Effect of Itopride on Semaglutide Gastroparesis
NCT07254715 on ClinicalTrials.gov · last registry update 2026-09-25
Finished 30 July 2026, after enrolling 60 people. Primary outcome, as filed: Residual gastric contents. The registry entry has been edited 2 times since then.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Ain Shams University
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2026-01-01
- Primary completion
- 2026-07-30 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-25 | Reporting date moved | 2026-04 → 2026-07-30 3 months later |
| 2026-09-25 | Status changed | RECRUITING → COMPLETED |
Primary outcome
Residual gastric contents
Conditions studied
Semaglutide-Induced Gastric Motility · Anesthesia
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.